Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
- DOI
- 10.1186/s10194-021-01376-7
- Published
- 2022 Feb 7
- Container
- The journal of headache and pain
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s10194-021-01376-7,
title = {Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.},
author = {McAllister P and Winner PK and Ailani J and Buse DC and Lipton RB and Chakhava G and Josiassen MK and Lindsten A and Mehta L and Ettrup A and Cady R},
year = {2022},
journal = {The journal of headache and pain},
doi = {10.1186/s10194-021-01376-7},
url = {https://doi.org/10.1186/s10194-021-01376-7}
}RIS
TY - JOUR TI - Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. AU - McAllister P AU - Winner PK AU - Ailani J AU - Buse DC AU - Lipton RB AU - Chakhava G AU - Josiassen MK AU - Lindsten A AU - Mehta L AU - Ettrup A AU - Cady R PY - 2022 JO - The journal of headache and pain DO - 10.1186/s10194-021-01376-7 UR - https://doi.org/10.1186/s10194-021-01376-7 ER -
APA
P, M., PK, W., J, A., DC, B., RB, L., G, C., MK, J., A, L., L, M., A, E., & R, C. (2022). Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.. The journal of headache and pain. https://doi.org/10.1186/s10194-021-01376-7
Source records
- pubmed · retrieved 2026-09-25T17:25:38.847Z